165 related articles for article (PubMed ID: 19952950)
1. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.
Heinze S; Egberts F; Rötzer S; Volkenandt M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Hinzpeter A; Hauschild A; Schaefer M
J Immunother; 2010 Jan; 33(1):106-14. PubMed ID: 19952950
[TBL] [Abstract][Full Text] [Related]
2. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
Capuron L; Ravaud A; Miller AH; Dantzer R
Brain Behav Immun; 2004 May; 18(3):205-13. PubMed ID: 15050647
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life before and during adjuvant interferon-α treatment for patients with malignant melanoma (DeCOG-trial).
Ziefle S; Egberts F; Heinze S; Volkenandt M; Schmid-Wendtner M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Heinz A; Hauschild A; Schaefer M
J Immunother; 2011 May; 34(4):403-8. PubMed ID: 21499123
[TBL] [Abstract][Full Text] [Related]
4. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha.
Schaefer M; Horn M; Schmidt F; Schmid-Wendtner MH; Volkenandt M; Ackenheil M; Mueller N; Schwarz MJ
Brain Behav Immun; 2004 Nov; 18(6):555-62. PubMed ID: 15331126
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
6. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment.
Beratis S; Katrivanou A; Georgiou S; Monastirli A; Pasmatzi E; Gourzis P; Tsambaos D
J Psychosom Res; 2005 Jan; 58(1):15-8. PubMed ID: 15771865
[TBL] [Abstract][Full Text] [Related]
7. Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-α and ribavirin therapy: a prospective evaluation.
Chapman J; Oser M; Hockemeyer J; Weitlauf J; Jones S; Cheung R
Am J Gastroenterol; 2011 Dec; 106(12):2123-32. PubMed ID: 21826113
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma.
Friebe A; Horn M; Schmidt F; Janssen G; Schmid-Wendtner MH; Volkenandt M; Hauschild A; Goldsmith CH; Schaefer M
Psychosomatics; 2010; 51(6):466-73. PubMed ID: 21051677
[TBL] [Abstract][Full Text] [Related]
9. Pre-cessation depressive mood predicts failure to quit smoking: the role of coping and personality traits.
Berlin I; Covey LS
Addiction; 2006 Dec; 101(12):1814-21. PubMed ID: 17156181
[TBL] [Abstract][Full Text] [Related]
10. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
[TBL] [Abstract][Full Text] [Related]
11. Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C.
Amodio P; De Toni EN; Cavalletto L; Mapelli D; Bernardinello E; Del Piccolo F; Bergamelli C; Costanzo R; Bergamaschi F; Poma SZ; Chemello L; Gatta A; Perini G
J Affect Disord; 2005 Jan; 84(1):93-8. PubMed ID: 15620390
[TBL] [Abstract][Full Text] [Related]
12. Measuring depressive symptoms among treatment-resistant seizure disorder patients: POMS Depression scale as an alternative to the BDI-II.
Griffith NM; Szaflarski JP; Szaflarski M; Kent GP; Schefft BK; Howe SR; Privitera MD
Epilepsy Behav; 2005 Sep; 7(2):266-72. PubMed ID: 16005686
[TBL] [Abstract][Full Text] [Related]
13. Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma.
Wong SF; Jakowatz JG; Taheri R
Ann Pharmacother; 2004 Oct; 38(10):1655-9. PubMed ID: 15304625
[TBL] [Abstract][Full Text] [Related]
14. [Depression during interferon therapy in chronic hepatitis C patients--a prospective study].
Otsubo T; Miyaoka H; Kamijima K; Onuki M; Ishii M; Mitamura K
Seishin Shinkeigaku Zasshi; 1997; 99(3):101-27. PubMed ID: 9136611
[TBL] [Abstract][Full Text] [Related]
15. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
Rudolf Z; Strojan P
Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
[TBL] [Abstract][Full Text] [Related]
16. Depression in hospitalized patients with malignant melanoma treated with interferon-alpha-2b: primary to induced disorders.
Navinés R; Gómez-Gil E; Puig S; Baeza I; De Pablo J; Martín-Santos R
Eur J Dermatol; 2009; 19(6):611-5. PubMed ID: 19709980
[TBL] [Abstract][Full Text] [Related]
17. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
Schaefer M; Schmidt F; Folwaczny C; Lorenz R; Martin G; Schindlbeck N; Heldwein W; Soyka M; Grunze H; Koenig A; Loeschke K
Hepatology; 2003 Feb; 37(2):443-51. PubMed ID: 12540795
[TBL] [Abstract][Full Text] [Related]
18. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
19. [Obesity, alexithymia, psychopathology and binge eating: a comparative study of 40 obese patients and 32 controls].
De Chouly De Lenclave MB; Florequin C; Bailly D
Encephale; 2001; 27(4):343-50. PubMed ID: 11686056
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.
Friebe A; Schwarz MJ; Schmid-Wendtner M; Volkenandt M; Schmidt F; Horn M; Janssen G; Schaefer M
J Immunother; 2007 Apr; 30(3):333-7. PubMed ID: 17414324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
